| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Multiple human Phase I/II trials at Imperial College London and other academic centers, including a JAMA Network Open randomized trial on hypoactive sexual desire disorder and JCEM mechanistic studies. No Phase III trials exist. |
10 / 25 |
| Sample Size | Individual studies are small — the foundational LH-pulsatility study used 4 men; the HSDD safety cohort enrolled 95 participants. Cumulative human exposure is modest for a compound with this much mechanistic interest. |
4 / 20 |
| Replication | LH/FSH stimulation effect has been replicated across multiple Imperial College London studies and independent groups. Sexual dimorphism findings (different efficacy by sex and menstrual cycle phase) add a layer of independently confirmed nuance. |
10 / 20 |
| Journal Impact Factor | Published in JCEM (IF ~6.5) and JAMA Network Open (IF ~13) — notably strong journal placement for a peptide still in early-stage human research. |
12 / 15 |
| Funding Independence | Predominantly academic and Imperial College London-affiliated research. No major commercial sponsor identified in the core human trials reviewed. |
7 / 10 |
| Population Diversity | Studies are small, single-site cohorts (healthy men, women with HSDD) — narrow population by necessity of the research stage. No broad demographic spread identified. |
1 / 5 |
| Researcher h-Index | Lead researchers in the Imperial College London reproductive endocrinology group have solid, established academic profiles consistent with category peers at this evidence stage. |
3 / 5 |